Drug news
NICE recommends Mepact for Osteosarcoma
NICE,the health technology appraisal institute for England and Wales, has published final guidance recommending Mepact (mifamurtide)from Takeda in combination with post-operative multi-agent chemotherapy as an option for treating high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults.
This was a reversal of an earlier decision.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.